Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

198

Participants

Timeline

Start Date

January 8, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions

UnresectableLocally Advanced or Metastatic Solid Tumors

Interventions

DRUG

IBI3005

Bispecific Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3005)

Trial Locations (1)

RECRUITING

Shandong Cancer Hospital & Institute, Jinan

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT06418061 - Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter